Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Atzpodien

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
Klinische Wochenschrift|January 4, 1990
Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasmsJ Atzpodien, H Kirchner
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignanciesJ Atzpodien, H Kirchner
Stem Cells (Dayton, Ohio)|November 1, 1993
T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cellsJ Atzpodien, S C Gulati
Cancer Biotherapy & Radiopharmaceuticals|June 1, 1997
Dose distribution of low-dose subcutaneous recombinant interleukin-2 affects the secondary release of interferon-gamma in vivoM Meffert, S Duensing, J Atzpodien
Medizinische Klinik (Munich, Germany : 1983)|April 12, 1996
[Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma]J Atzpodien, H Kirchner, H Poliwoda
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapyA Schomburg, H Kirchner, J Atzpodien
Anti-Cancer Drugs|October 1, 1993
Low dose megestrol acetate can abrogate cachexia in advanced tumor patients receiving systemic interferon-alpha and/or interleukin-2 based antineoplastic therapyM Ackermann, H Kirchner, J Atzpodien
Acta Haematologica|January 1, 1993
Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimensA Schomburg, H Kirchner, J Atzpodien
Seminars in Oncology|October 1, 1991
alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patientsJ Atzpodien, H Poliwoda, H Kirchner
Der Urologe. Ausg. A|November 13, 2002
[Molecular genetic changes in renal cell carcinomas]N Buentig, S Störkel, J Atzpodien
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
Klinische Wochenschrift|January 4, 1990
Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasmsJ Atzpodien, H Kirchner
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignanciesJ Atzpodien, H Kirchner
Stem Cells (Dayton, Ohio)|November 1, 1993
T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cellsJ Atzpodien, S C Gulati
Cancer Biotherapy & Radiopharmaceuticals|June 1, 1997
Dose distribution of low-dose subcutaneous recombinant interleukin-2 affects the secondary release of interferon-gamma in vivoM Meffert, S Duensing, J Atzpodien
Medizinische Klinik (Munich, Germany : 1983)|April 12, 1996
[Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma]J Atzpodien, H Kirchner, H Poliwoda
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapyA Schomburg, H Kirchner, J Atzpodien
Anti-Cancer Drugs|October 1, 1993
Low dose megestrol acetate can abrogate cachexia in advanced tumor patients receiving systemic interferon-alpha and/or interleukin-2 based antineoplastic therapyM Ackermann, H Kirchner, J Atzpodien
Acta Haematologica|January 1, 1993
Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimensA Schomburg, H Kirchner, J Atzpodien
Seminars in Oncology|October 1, 1991
alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patientsJ Atzpodien, H Poliwoda, H Kirchner
Der Urologe. Ausg. A|November 13, 2002
[Molecular genetic changes in renal cell carcinomas]N Buentig, S Störkel, J Atzpodien
Pageof 12